Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07164443 · ClinicalTrials.gov registry record · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 663
- Enrollment target
- 20
- Study locations
NCT07164443 is a Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 663 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT07164443, a Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 663 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Pasritamig
- DRUG Best Supportive Care (BSC)
Study Locations (20)
New York
- NYU Langone Hospitals - Brooklyn
- NYU Langone Hospital Long Island - Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center - New York
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
- Keystone Urology Specialists - Lancaster
- UPMC Cancer Centers - Pittsburgh
South Carolina
- Gibbs Cancer Center and Research Institute Pelham - Greer
- Carolina Urologic Research Center - Myrtle Beach
- Gibbs Cancer Center - Spartanburg
Colorado
- Rocky Mountain Cancer Centers - Aurora
- Colorado Clinical Research - Lakewood
Florida
- Bay Pines VA Healthcare System - Bay Pines
- Florida Cancer Specialists & Research Institute - Fort Myers
Oregon
- Compass Oncology - Portland
- Oregon Urology Institute - Springfield
Louisiana
- East Jefferson General Hospital - Metairie
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07164443
The ClinicalTrials.gov registry entry for NCT07164443 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 663 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-resistant Prostate Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07164443 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Pennsylvania, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07164443 about?
NCT07164443 is a clinical study titled "A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant pro...
What is the current status of trial NCT07164443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 663 participants. The study started on 2025-09-02. Estimated completion is 2028-05-30.
What conditions does trial NCT07164443 study?
This clinical trial studies the following conditions: Metastatic Castration-resistant Prostate Neoplasms.
What interventions are being tested in trial NCT07164443?
The interventions under investigation include: Placebo (OTHER), Pasritamig (BIOLOGICAL), Best Supportive Care (BSC) (DRUG).
Who is sponsoring clinical trial NCT07164443?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07164443 being conducted?
This trial has 20 study locations across Colorado, Florida, Louisiana, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-resistant Prostate Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.